Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02668-y)

Lindsay B. Kilburn; Dong Anh Khuong-Quang; Jordan R. Hansford; Daniel Landi; Jasper van der Lugt; Sarah E.S. Leary; Pablo Hernáiz Driever; Simon Bailey; Sébastien Perreault; Geoffrey McCowage; Angela J. Waanders; David S. Ziegler; Olaf Witt; Patricia A. Baxter; Hyoung Jin Kang; Timothy E. Hassall; Jung Woo Han; Darren Hargrave; Andrea T. Franson; Michal Yalon Oren; Helen Toledano; Valérie Larouche; Cassie Kline; Mohamed S. Abdelbaki; Nada Jabado; Nicholas G. Gottardo; Nicolas U. Gerber; Nicholas S. Whipple; Devorah Segal; Susan N. Chi; Liat Oren; Enrica E.K. Tan; Sabine Mueller; Izzy Cornelio; Lisa McLeod; Xin Zhao; Ashley Walter; Daniel Da Costa; Peter Manley; Samuel C. Blackman; Roger J. Packer; Karsten Nysom

doi:10.1038/s41591-024-02910-1

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02668-y)

Lindsay B. Kilburn, Dong Anh Khuong-Quang, Jordan R. Hansford, Daniel Landi, Jasper van der Lugt, Sarah E.S. Leary, Pablo Hernáiz Driever, Simon Bailey, Sébastien Perreault, Geoffrey McCowage, Angela J. Waanders, David S. Ziegler, Olaf Witt, Patricia A. Baxter, Hyoung Jin Kang, Timothy E. Hassall, Jung Woo Han, Darren Hargrave, Andrea T. Franson, Michal Yalon OrenHelen Toledano, Valérie Larouche, Cassie Kline, Mohamed S. Abdelbaki, Nada Jabado, Nicholas G. Gottardo, Nicolas U. Gerber, Nicholas S. Whipple, Devorah Segal, Susan N. Chi, Liat Oren, Enrica E.K. Tan, Sabine Mueller, Izzy Cornelio, Lisa McLeod, Xin Zhao, Ashley Walter, Daniel Da Costa, Peter Manley, Samuel C. Blackman, Roger J. Packer, Karsten Nysom

Research output: Contribution to journal › Comment/debate

Abstract

published online 17 November 2023. In the version of the article initially published, in the third paragraph of the “RAPNO criteria (secondary endpoints)” section, the text now reading “Thirteen (17.1%) patients initially had a best overall response of PD…” originally read “Thirty-one patients initially had PD…”. This has been corrected in the HTML and PDF versions of the article.

Original language	English
Pages (from-to)	1500
Number of pages	1
Journal	Nature medicine
Volume	30
Issue number	5
DOIs	https://doi.org/10.1038/s41591-024-02910-1
State	Published - May 2024

Access to Document

10.1038/s41591-024-02910-1

Cite this

Kilburn, L. B., Khuong-Quang, D. A., Hansford, J. R., Landi, D., van der Lugt, J., Leary, S. E. S., Driever, P. H., Bailey, S., Perreault, S., McCowage, G., Waanders, A. J., Ziegler, D. S., Witt, O., Baxter, P. A., Kang, H. J., Hassall, T. E., Han, J. W., Hargrave, D., Franson, A. T., ... Nysom, K. (2024). Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02668-y). Nature medicine, 30(5), 1500. https://doi.org/10.1038/s41591-024-02910-1

@article{db023dc8dc7440128ac96bd71987386b,

title = "Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02668-y)",

abstract = "published online 17 November 2023. In the version of the article initially published, in the third paragraph of the “RAPNO criteria (secondary endpoints)” section, the text now reading “Thirteen (17.1%) patients initially had a best overall response of PD…” originally read “Thirty-one patients initially had PD…”. This has been corrected in the HTML and PDF versions of the article.",

author = "Kilburn, {Lindsay B.} and Khuong-Quang, {Dong Anh} and Hansford, {Jordan R.} and Daniel Landi and {van der Lugt}, Jasper and Leary, {Sarah E.S.} and Driever, {Pablo Hern{\'a}iz} and Simon Bailey and S{\'e}bastien Perreault and Geoffrey McCowage and Waanders, {Angela J.} and Ziegler, {David S.} and Olaf Witt and Baxter, {Patricia A.} and Kang, {Hyoung Jin} and Hassall, {Timothy E.} and Han, {Jung Woo} and Darren Hargrave and Franson, {Andrea T.} and {Yalon Oren}, Michal and Helen Toledano and Val{\'e}rie Larouche and Cassie Kline and Abdelbaki, {Mohamed S.} and Nada Jabado and Gottardo, {Nicholas G.} and Gerber, {Nicolas U.} and Whipple, {Nicholas S.} and Devorah Segal and Chi, {Susan N.} and Liat Oren and Tan, {Enrica E.K.} and Sabine Mueller and Izzy Cornelio and Lisa McLeod and Xin Zhao and Ashley Walter and {Da Costa}, Daniel and Peter Manley and Blackman, {Samuel C.} and Packer, {Roger J.} and Karsten Nysom",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = may,

doi = "10.1038/s41591-024-02910-1",

language = "English",

volume = "30",

pages = "1500",

journal = "Nature medicine",

issn = "1078-8956",

number = "5",

}

Kilburn, LB, Khuong-Quang, DA, Hansford, JR, Landi, D, van der Lugt, J, Leary, SES, Driever, PH, Bailey, S, Perreault, S, McCowage, G, Waanders, AJ, Ziegler, DS, Witt, O, Baxter, PA, Kang, HJ, Hassall, TE, Han, JW, Hargrave, D, Franson, AT, Yalon Oren, M, Toledano, H, Larouche, V, Kline, C, Abdelbaki, MS, Jabado, N, Gottardo, NG, Gerber, NU, Whipple, NS, Segal, D, Chi, SN, Oren, L, Tan, EEK, Mueller, S, Cornelio, I, McLeod, L, Zhao, X, Walter, A, Da Costa, D, Manley, P, Blackman, SC, Packer, RJ & Nysom, K 2024, 'Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02668-y)', Nature medicine, vol. 30, no. 5, pp. 1500. https://doi.org/10.1038/s41591-024-02910-1

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02668-y). / Kilburn, Lindsay B.; Khuong-Quang, Dong Anh; Hansford, Jordan R. et al.
In: Nature medicine, Vol. 30, No. 5, 05.2024, p. 1500.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Author Correction

T2 - The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02668-y)

AU - Kilburn, Lindsay B.

AU - Khuong-Quang, Dong Anh

AU - Hansford, Jordan R.

AU - Landi, Daniel

AU - van der Lugt, Jasper

AU - Leary, Sarah E.S.

AU - Driever, Pablo Hernáiz

AU - Bailey, Simon

AU - Perreault, Sébastien

AU - McCowage, Geoffrey

AU - Waanders, Angela J.

AU - Ziegler, David S.

AU - Witt, Olaf

AU - Baxter, Patricia A.

AU - Kang, Hyoung Jin

AU - Hassall, Timothy E.

AU - Han, Jung Woo

AU - Hargrave, Darren

AU - Franson, Andrea T.

AU - Yalon Oren, Michal

AU - Toledano, Helen

AU - Larouche, Valérie

AU - Kline, Cassie

AU - Abdelbaki, Mohamed S.

AU - Jabado, Nada

AU - Gottardo, Nicholas G.

AU - Gerber, Nicolas U.

AU - Whipple, Nicholas S.

AU - Segal, Devorah

AU - Chi, Susan N.

AU - Oren, Liat

AU - Tan, Enrica E.K.

AU - Mueller, Sabine

AU - Cornelio, Izzy

AU - McLeod, Lisa

AU - Zhao, Xin

AU - Walter, Ashley

AU - Da Costa, Daniel

AU - Manley, Peter

AU - Blackman, Samuel C.

AU - Packer, Roger J.

AU - Nysom, Karsten

PY - 2024/5

Y1 - 2024/5

N2 - published online 17 November 2023. In the version of the article initially published, in the third paragraph of the “RAPNO criteria (secondary endpoints)” section, the text now reading “Thirteen (17.1%) patients initially had a best overall response of PD…” originally read “Thirty-one patients initially had PD…”. This has been corrected in the HTML and PDF versions of the article.

AB - published online 17 November 2023. In the version of the article initially published, in the third paragraph of the “RAPNO criteria (secondary endpoints)” section, the text now reading “Thirteen (17.1%) patients initially had a best overall response of PD…” originally read “Thirty-one patients initially had PD…”. This has been corrected in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85187117033&partnerID=8YFLogxK

U2 - 10.1038/s41591-024-02910-1

DO - 10.1038/s41591-024-02910-1

M3 - Comment/debate

C2 - 38467878

AN - SCOPUS:85187117033

SN - 1078-8956

VL - 30

SP - 1500

JO - Nature medicine

JF - Nature medicine

IS - 5

ER -

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02668-y)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this